Literature DB >> 2829280

The metabolism of synthetic leukotriene B4 in synovial fluid and whole human blood.

M J Forrest1, D Burton, P M Brooks.   

Abstract

The metabolism in vitro of synthetic leukotriene B4 (LTB4) in synovial fluid from rheumatoid arthritis and osteoarthritis patients and in whole blood from these same patient groups and from normal volunteers has been studied. A linear relationship existed between a plot of the time of incubation of samples with LTB4 and the percentage of the initial concentration of LTB4 at each time point. The slope of this line, the rate constant for metabolism, has been used to compare different samples. LTB4 was metabolised more rapidly in the synovial fluid of rheumatoid arthritis patients than osteoarthritis patients. Furthermore, LTB4 was metabolised more rapidly in the blood of rheumatoid arthritis patients than either osteoarthritis patients or normal volunteers. These differences in metabolism correlate with the polymorphonuclear leukocyte (PMN) and albumin content of samples. It is suggested that binding of LTB4 to albumin in vivo will in part determine the available concentration of LTB4 in inflammatory lesions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2829280     DOI: 10.1016/0090-6980(87)90088-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  3 in total

1.  Effects of non-steroidal anti-inflammatory drugs on polymorphonuclear leukocyte functions in vitro: focus on fenamates.

Authors:  H Kankaanranta; E Moilanen; H Vapaatalo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

2.  Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions.

Authors:  H Kankaanranta; E Moilanen; H Vapaatalo
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

3.  Lipoxygenase products in inflammatory synovial fluids and other exudates.

Authors:  P B Costello; A N Baer; F A Green
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.